Based on the multiple clinical associations and the functional difference between the subsets we observed, both CD226 blockade and enhancing the intrinsic inhibitory properties of TIGIT in PBC patients are potential therapeutic targets for inhibiting terminally differentiated T cells. The gene discussed is TIGIT; the disease is primary biliary cholangitis.